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Introduction
Glaucoma is a chronic progressive
optic neuropathy, in which the rate of
change of structural and functional
abnormalities varies greatly from
patient to patient (Heijl et al. 2002;
Tuulonen et al. 2003). In the majority
of patients the abnormalities progress
slowly over a period of years. How-
ever, in some patients the disease may
lead rapidly to serious visual disability
and blindness. Glaucoma reduces
patients’ health-related quality of life
(HRQoL) mainly in far-advanced sta-
ges of the disease; in other words, if
the visual ﬁeld damage is severe in
both eyes (Tuulonen et al. 2003).
Although the purpose of therapy is
to prevent glaucoma-induced visual
disability, high-quality studies using
severe visual impairment as an end-
point are lacking (Fleming et al.
2005). However, there is evidence of
treatment efﬁcacy in primary open
angle glaucoma from randomized con-
trolled trials, which have used visual
ﬁeld decay as a surrogate endpoint
(Heijl et al. 2002; Maier et al. 2005).
The evidence of treatment efﬁcacy in
normal tension glaucoma is not con-
sistent (CNTG 1998; Spry et al. 2001;
Maier et al. 2005).
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ABSTRACT.
Purpose: To assess the cost effectiveness and cost utility of an organized
screening programme for glaucoma. The previous cost-effectiveness studies of
screening show inconsistent results, and the cost utility of screening has not
been assessed.
Methods: An organized screening programme was simulated using Markov
modelling in a population aged 50–79 years at 5 year intervals. The pro-
gramme ended when the subjects reached the age of 80 years. The comparator
was opportunistic case ﬁnding. The main outcome measures were cases and
years of severe visual disability avoided, quality-adjusted life years (QALYs)
gained and direct healthcare and non-healthcare costs.
Results: The incremental cost of 1 year of avoided visual disability by screen-
ing was €32 602. The cost of one QALY gained by screening was €9023 with
a discount rate of 5%. During the average 20 year time horizon considered,
the cumulative incremental costs of screening in a population of 1 million peo-
ple would be €30 million, producing 3360 incremental QALYs and 930 years
of avoided visual disability for 701 persons. The results were sensitive to the
estimates of several parameters, especially screening cost and speciﬁcity of
screening tests (96–99% speciﬁcity required).
Conclusion: An organized screening programme could be a cost-effective strat-
egy especially in older age groups, in which screening is clearly more likely to
be acceptable to decision makers at any level in terms of their willingness to
pay for a QALY. Modelling includes some uncertainty especially concerning
the speciﬁcity of diagnostic tests and screening cost.
Key words: Markov model – QALY – visual disability – willingness to pay
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The prevalence of glaucoma increa-
ses with age and is approximately
1.5% in the Caucasian population
over 50 years of age (Tuulonen et al.
2003). The ratio of suspected glau-
coma to manifest glaucoma has been
estimated to be 7 : 1, but can be even
higher (Leske & Hawkins 1994). The
introduction of new glaucoma medica-
tions has increased annual costs con-
siderably (de Natale et al. 2004),
probably because of treating more
patients at risk of developing glau-
coma rather than those with manifest
glaucoma (Tuulonen 2004). Only a
few health economic studies have been
conducted despite the increasing eco-
nomic burden of glaucoma (Kobelt
2002; Tuulonen & Sintonen 2006).
According to epidemiological stu-
dies, at least half of subjects with glau-
coma are unaware of their disease
(Quigley 1996). In most countries glau-
coma is usually detected by opportu-
nistic case ﬁnding without systematic
mass screening programmes. Although
several methods are available for glau-
coma diagnostics, no single screening
test is sufﬁcient to discriminate persons
with and without glaucoma (Wormald
& Rauf 1995; Spry et al. 2001). A com-
bination of several tests has been sug-
gested and used in the three studies
published on the cost effectiveness of
glaucoma screening in the USA, Can-
ada and the UK (Gottlieb et al. 1983;
Boivin et al. 1996; Tuck & Crick 1997).
However, the results of these studies
are not consistent and none assessed
the cost utility of screening.
The purpose of this study is to
assess – mainly from the viewpoint of
Finnish healthcare system – the cost
effectiveness and cost utility of an
organized programme for screening
and treatment for glaucoma compared
to opportunistic case ﬁnding.
Methods
Simulated screening programme
A screening programme was simulated
at 5 year intervals1 in a population
aged 50–79 years and followed until
the age of 89 or death. Thus, the old-
est age group of 75–79 years would be
invited to screening once and the
youngest age group of 50–54 years six
times. The examinations carried out in
the screening arm were measurement
of intraocular pressure, fundus evalua-
tion,2 autorefraction and visual ﬁeld
examination. In the positive cases the
same tests are carried out anew (sec-
ond screening) to conﬁrm the ﬁndings.
Clinical studies have shown that the
clinical signiﬁcance of a single abnor-
mal visual ﬁeld is small and half of
the visual ﬁeld abnormalities cannot
be conﬁrmed when retested (Tuulonen
et al. 2003). In the follow-up of diag-
nosed glaucoma patients, tonometry
would be performed twice a year, ima-
ging and automated perimetry once in
two years (Tuulonen et al. 2003). The
screening arm (Fig. 1) was compared
to the current opportunistic case ﬁnd-
ing in Finland.
Opportunistic case ﬁnding in the Finnish
healthcare system
Although the Finnish healthcare sys-
tem covers the whole population and
its services are mainly tax-ﬁnanced, its
main shortcomings are unequal access
to care and large variations in the dis-
tribution of healthcare services (Isol-
auri 2000; Keskima¨ki 2001). The
number of visits to the private sector,
especially within ophthalmology, has
increased constantly since the 1980s.
Currently two thirds of all eye
transactions are performed in the pri-
vate sector.
Before March 2005 the majority of
glaucoma patients did not have access
to public care (Brommels et al. 2004).
Because the services – mainly paid out
of pocket – were delivered in the pri-
vate sector, very little is known about
their content. However, the Social
Insurance Institution registers all
patients receiving reimbursement for
glaucoma medication as well as the
number of reimbursed visual ﬁeld and
photographic examinations in the
private sector. Based on these data it
can be roughly estimated that if all
images and visual ﬁelds in the private
sector were taken because of glaucoma
(which is, of course, not the case),
only about 15% of glaucoma patients
had their visual ﬁelds taken once a
year and another 15% of patients had
images taken every 1–2 years together
with visual ﬁelds.
Markov model
A Markov model (Treeage Pro 2004;
Treeage Software, Williamstown,
Massachusetts, USA) was built for
economic evaluation including follow-
up and treatment. The model consists
of 14 Markov states, which describe
all relevant outcomes in the screening
and treatment process (Tables 1 and
2, Fig. S1). Simulated cohorts enter
the model in states 1, 3, 4, 6, 8, 10
and 11 on the basis of estimated pre-
valence (Table 3). The arm for oppor-
tunistic case ﬁnding does not include
states 2, 5, 9 and 12. The Markov
cycle was set at 5 years. Therefore, all
transitions from one state to another
take place in both arms in 5 year
cycles based on 5 year probabilities.
Those not participating in screening
follow the pathways of opportunistic
case ﬁnding. The same estimates of
prevalence and incidence are used in
both arms; similarly, the HRQoL
scores and costs associated with the
same Markov states in both arms are
the same. Screening and treatment
affect the probabilities of moving
from one state to another and are
thus different in the opportunistic case
ﬁnding arm. The time horizon of the
model varied from 40 years in the
youngest age group and 10 years in
the oldest (some 20 years on average).
All variables in the model were
subjected to one-way sensitivity
1The rationale behind the 5 year screening
interval is as follows. First visual defects are
expected to develop in 5% of subjects with
ocular hypertension during the 5 year inter-
val. In patients under treatment, the mean
time between the appearance of the ﬁrst vis-
ual changes and blindness is estimated to be
30–40 years (Tuulonen et al. 2003).
2The rationale behind the selected fundus
evaluation methods is as follows. Firstly, the
wide-angle digital imaging is the same tech-
nique that is already used widely and rou-
tinely for diabetic screening in Finland. The
advantage of imaging compared to ophthalm-
oscopic evaluation is the documentation of
fundus ﬁndings for later review. In one wide-
angle photograph, both optic disc and retinal
nerve ﬁbre layer can be evaluated simulta-
neously. When they are evaluated together
with the visual ﬁelds, the ‘two out of three’
rule is applicable – as described in detail in
the Finnish Current Care Guideline (Tuulo-
nen et al. 2003) – i.e. options when at least
two of three ﬁndings in the nerve ﬁbre layer,
optic disc and visual ﬁeld are (ab)normal and
concordant. Secondly, the Heidelberg Retina
Tomograph is the only one of the new ima-
ging instruments that has been used for
screening purposes (Robin et al. 2005). It also
images the retinal nerve ﬁbre layer around
the optic disc.
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analysis. Threshold analyses were
carried out for variables to which
the results were most sensitive. Prob-
abilistic sensitivity analysis (10 000
Monte Carlo simulations) was per-
formed to evaluate the degree of
uncertainty in the results. A normal
distribution was assumed for age-spe-
ciﬁc variables (estimates of preval-
ence, incidence and HRQoL scores),
beta distribution for sensitivity and
speciﬁcity, and gamma distribution
for cost variables. Details of distri-
bution parameters are given in
Tables 4 and 5. Results are given as
incremental cost-effectiveness and
cost-utility ratios (ICER ⁄ ICUR),
cost-effectiveness plane and cost-
effectiveness acceptability curves in
different age groups.
Data sources and assumptions
The prevalence of glaucoma and diag-
nosed glaucoma in different age
groups was estimated from the equa-
tion by Quigley & Vitale (1997); the
prevalence of drug-treated ocular
hypertension without glaucoma was
estimated using medication reimburse-
ment data from the register of the
Finnish Social Insurance Institution
(2003) (Table 3).
The 5 year incidences of new glau-
coma cases in different age groups
were calculated from the age-speciﬁc
prevalence estimates using the formula
(Px + 1 ) Px) ⁄ 1 ) Px, where P
denotes prevalence and subscript age
group (Leske et al. 1981). The inci-
dence of suspected glaucoma was
estimated to be six times higher (Tielsch
et al. 1991). In the model, only
patients with manifest glaucoma3 (i.e.
not those with ocular hypertension)
and false positives produced by
screening are treated. The mortality of
glaucoma patients was assumed to
match the normal population (Gro-
dum et al. 2004). All other probabili-
ties used in the model are given in
Table 4.
The resource requirements and costs
for the screening programme include
personnel, equipment, premises, trav-
elling and (in the case of visual dis-
ability) social services (Tables 5 and
6). Therefore, the costs include direct
healthcare and non-healthcare costs.
The costs of fundus evaluation were
calculated in two ways: (1) for one
wide-angle black-and-white red-free
image per eye (Tuulonen et al. 1990);
and (2) for Heidelberg Retina Tomo-
graph (Robin et al. 2005). The soft-
ware and hardware for the storage of
digital fundus images has been des-
cribed in detail elsewhere (Tuulonen
et al. 2000). The screening costs for
perimetry were calculated using both
the Humphrey SITA-Fast program
(Carl Zeiss Meditec, Dublin, CA,
USA) and Frequency Doubling Tech-
nology (FDT). The cost per screen
was €37 using Humphrey perimetry
and €29 using FDT (Table 6). Because
the screening programme targets
mainly older age groups, productivity
costs were not included. All costs are
in Euro at 2003 price level.
In the base case analysis, costs and
health beneﬁts were discounted at 5%
(Ministry of Social Affairs and Health
2004) and at 3.5%, as per the NICE
recommendation (NICE 2004).
Population  
aged 50–79 
years 
including patients 
with 
diagnosis of 
glaucoma
80% participate 
in the 
first screening 
20% do not 
participate in 
the screening 
Negative 
screening 
 (70%) 
Unsuccessful 
or unreliable 
test results 
 (20%) 
Positive 
1. screening 
 (10%) 
New screenings 
with 5 year 
intervals 
Opportunistic 
case finding 
Negative 
2. screening 
Positive 
2. screening: 
prevalences by  
 age groups 
(Table 3)  
New screenings 
with 5-year 
intervals 
1. Treatment 
2. Follow-up  
IOP every 6 months
Tests every 2 years
New progressive cases 
(both eyes) per 5 years 
Treated eyes 34% 
Untreated eyes 41%
(please see Table 4) 
Bilateral visual 
disability 
12% in >70 years of 
age
Opportunistic 
case finding 
Fig. 1. Flow chart of the simulated screening protocol.
3The rationale behind treating only patients
with manifest glaucoma in the model is as
follows. The performance of current glau-
coma care can be questioned for several rea-
sons: (1) several epidemiological studies have
shown that at least half of glaucoma patients
are undiagnosed; (2) simultaneously, more
than half of the patients currently treated for
glaucoma do not have the disease (Mukesh
et al. 2002); and (3) more than half of
patients with newly diagnosed glaucoma have
seen an ophthalmologist, but their disease
was not diagnosed (Grodum et al. 2002;
Mukesh et al. 2002). Obviously, if patients with
mere risk were treated in the model, it would
have affected the cost effectiveness adversely.
The main idea in the model was to target the
limited resources at ﬁnding and treating only
those patients with manifest disease.
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Patient utilities
The HRQoL scores, measured by the
generic 15D instrument (Sintonen
2001; http://www.15D-instrument.net)
in the 5 year age groups in different
Markov states, were estimated with
regression analyses with age, age
squared and dummies for Markov
states as independent variables. The
data (on ﬁle) came from the Finnish
Health 2000 Health Examination Sur-
vey, which was representative of the
Finnish population aged 30 years and
over (n ¼ 6269). The survey respond-
ents were assigned to different Mark-
ov states, as described in Table 1. The
age-speciﬁc HRQoL scores in different
Markov states are presented in
Table 7.
Results
The incremental cost of 1 year of
avoided visual disability by screening
in comparison to opportunistic case
ﬁnding was €32 602 (ICER of screen-
ing). The cost of one quality-adjusted
life year (QALY) gained by screening
in comparison to opportunistic case
ﬁnding was €9024 with a discount rate
of 5% and €7582 with a discount rate
of 3.5% (ICUR of screening)
(Table 8). The cost varied from
€52517 per QALY gained in the
youngest cohort to strong dominance
in the three oldest cohorts: in these
three oldest cohorts, screening strategy
was both less costly and more effect-
ive than opportunistic case ﬁnding.
During the time horizon of the
model, in the target population of
1 million the cumulative incremental
costs of screening (i.e. costs exceeding
opportunistic case ﬁnding) would be
€30 million (€24.5 million) producing
3360 (6320) incremental QALYs and
930 (3480) years of avoided visual dis-
ability by 701 persons (undiscounted
values in parentheses).
One-way sensitivity analyses
(Table 9) revealed that the results
were sensitive to the estimates of spe-
ciﬁcity of screening tests, screening
cost, discount rate, follow-up cost,
prevalence of suspected glaucoma and
prevalence of glaucoma. The speciﬁci-
ties can be only slightly lower than
assumed in the base case in younger
age groups before screening becomes
more costly and less effective. There is
much more tolerance in this respect in
older age groups (Table 10). Varying
participation rates from the baseline
80% to 60% and 100% produced
ICERs of €7581 and €10 261, respect-
ively. The results were quite robust
for variation in all other variables,
including HRQoL scores.
Probabilistic sensitivity analysis of
base case showed that in 24% of the
simulated cases screening was strongly
dominant (i.e. both less costly and
more effective); screening was more
costly and more effective in 47% of
Table 1. Deﬁnitions of the Markov states and indications of whether the individuals in the screening arm are invited to further screening (S), no
further screening (no S) or whether they follow the opportunistic case-ﬁnding (OCF) arm.
Markov state Description of the state based on data from the Finnish Health 2000 Health Examination Survey (n ¼ 6269)
(1) Healthy A person without self-reported glaucoma (S)
(2) Healthy, failed screening Same as (1) but screening failed for one reason or another (OCF)
(3) Suspected glaucoma,
no treatment
A person with self-reported glaucoma (conﬁrmed by an ophthalmologist) and vision at level <5 on the 15D
dimension of vision is followed up by an ophthalmologist, but receives no daily drug treatment and has not
been treated with laser or operation (S)
(4) Drug-treated ocular
hypertension, no glaucoma
Same as (6) (S or no S depending on the screening result)
(5) Suspected glaucoma,
failed screening
Same as (3) but screening failed for one reason or another (OCF)
(6) Drug-treated glaucoma A person with self-reported glaucoma (conﬁrmed by an ophthalmologist) and vision at level <5 on the 15D
dimension of vision is followed up by an ophthalmologist, has visited an ophthalmologist less than three
times during the last year and receives daily drug treatment, but has not been treated with laser or
operation (no S)
(7) Laser-treated or operated
glaucoma
A person with self-reported glaucoma (conﬁrmed by an ophthalmologist) and vision at level <5 on the 15D
dimension of vision who has been treated with laser or operation (no S)
(8) Undiagnosed glaucoma A person with self-reported glaucoma (conﬁrmed by an ophthalmologist) and vision at level <5 on the 15D
dimension of vision is not followed up by an ophthalmologist, receives no daily drug treatment
and has not been treated with laser or operation (S)
(9) Undiagnosed glaucoma,
failed screening
Same as (8) but screening failed for one reason or another (OCF)
(10) Drug-treated glaucoma
with progression
A person with self-reported glaucoma (conﬁrmed by an ophthalmologist) and vision at level <5 on the 15D
dimension of vision is followed up by an ophthalmologist, has visited an ophthalmologist at least three
times during the last year and receives daily drug treatment but has not been treated with laser or
operation (no S)
(11) Undiagnosed glaucoma
with progression
Same as (8) (S)
(12) Undiagnosed glaucoma
with progression,
failed screening
Same as (8) but screening failed for one reason or another (OCF)
(13) Severe visual disability A person with self-reported glaucoma (conﬁrmed by an ophthalmologist) and vision at level 5 on the
15D dimension of vision (blind or almost blind) (no S)
S, will be invited to further screening; no S, will not be invited for further screening; OCF, follows the opportunistic case-ﬁnding arm.
Vision at level 5 on the 15D dimension of vision ¼ blind or almost blind.
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the simulated cases (Fig. 2). In the
oldest age group (75–79 years) screen-
ing was both less costly and more
effective in 80% of simulated cases;
this was true for only 5% of simulated
cases in the youngest age group (50–
54 years) (Fig. 3). Cost-effectiveness
acceptability curves in Fig. 4 reveal
clearly the big differences between the
age groups in the probability of
screening being considered cost effect-
ive. At any level of societal willingness
to pay for a QALY, the probability of
screening being acceptable is clearly
higher in older age groups.
Discussion
Main ﬁndings
Our analysis suggests that an organ-
ized glaucoma screening programme,
as outlined earlier in this article, could
be a cost-effective strategy compared
to opportunistic case ﬁnding in Fin-
land, especially in older age groups.
However, this conclusion is to some
extent surrounded by uncertainty and
depends largely on the high speciﬁcity
of screening tests. In younger age
groups the speciﬁcity can be only
slightly lower than assumed in the
base case analysis before screening
becomes more costly and less effect-
ive. In older groups there is more tol-
erance in this respect (Table 10). At
any level of decision makers’ willing-
ness to pay for a QALY, the probabil-
ity of screening being acceptable to
them is clearly higher in older age
groups (Fig. 4).
There are rather obvious reasons
for this perhaps counterintuitive
result. The oldest age groups have a
much higher prevalence and incidence
of progressive manifest glaucoma
than the younger age groups. Simul-
taneously, the older subjects also
have a higher probability of being
treated for ocular hypertension with-
out glaucoma (Table 3). Because the
oldest age groups are screened in the
model only once (75–79 years) or
twice (70–74 years), the cases with
manifest glaucoma will be found and
treated, and will have time to beneﬁt
from treatment. In the model, ther-
apy will not be initiated or will be
withdrawn from patients with ocular
hypertension. This approach of treat-
ing only manifest glaucoma (i.e. not
the risk of the disease) saves a lot ofT
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money without sacriﬁcing a great
deal of beneﬁt in the oldest age
groups.
On the other hand, the younger age
groups have a low prevalence and
incidence of glaucoma and their dis-
ease – on average – progresses slower
than in the older patients with more
severe damage. Because the younger
patients attend screening several times,
they incur substantial costs without
beneﬁting much until their older
years. Because of discounting, this
beneﬁt is further reduced consider-
ably. The cost-effectiveness acceptabil-
ity curve in the oldest age group is
almost horizontal at the probability
level of close to 1 (Fig. 4) because
screening is strongly dominant in this
age group. Screening produces net
beneﬁts at the same time as it saves
costs (80% of simulated cases are in
Quadrant IV in Fig. 3). Therefore,
screening is worth implementing
regardless of the level of willingness to
pay because it would free resources
for other uses.
Strengths of the study
To our knowledge, this is the ﬁrst pub-
lished study applying Markov model-
ling to assess the cost utility of
glaucoma screening and use a generic
quality of life instrument that allows
comparisons across different condi-
tions. Because of a lack of adequate
evidence on the values of most of the
important parameters, a model was
built to explore the effect of these
parameters and the uncertainty around
them on the cost utility of screening.
The model considers the whole
chain of outcomes from screening to
visual disability and similarly the full
range of costs associated with this
chain. The effects of assumptions and
uncertainties were tested extensively
Table 3. The age-speciﬁc prevalence estimates serving as probabilities of entry to the screening
and opportunistic case-ﬁnding arms: (1) estimated prevalence of glaucoma according to Quigley
& Vitale (1997); (2) prevalence of currently diagnosed glaucoma (cases identiﬁed by the oppor-
tunistic case ﬁnding, i.e. 50% of prevalent cases); (3) in the opportunistic case-ﬁnding arm, the
prevalence of drug-treated ocular hypertension without glaucoma (Social Insurance Institution
2003).
Age group
Prevalence of
glaucoma (%) (1)
Prevalence of diagnosed
glaucoma (%) (2)
Drug-treated hypertension,
no glaucoma (%) (3)
50–54 0.7 0.4 0.2
55–59 1.0 0.5 0.5
60–64 1.4 0.7 1.2
65–69 2.0 1.0 2.0
70–74 2.8 1.4 3.6
75–79 3.7 1.9 5.5
80–84 4.8 2.4 7.4
85–89 6.1 3.1 15.8
Table 4. Probabilities (%) used in the Markov model.*
Variable Base case analysis Range for sensitivity analysis Distribution parameters for PSA
Sensitivity of 1st screening1 85 60–95 Beta (68, 12)
Speciﬁcity of 1st screening1 90 75–99 Beta (72, 8)
Sensitivity of 2nd screening1 99 60–99 Beta (49.5, 0.5)
Speciﬁcity of 2nd screening1 80 70–90 Beta (128, 32)
Overall sensitivity after 1st and 2nd screening 84
Overall speciﬁcity after 1st and 2nd screening 98
Participation rate in screening1 80 60–100 Normal (0.8, 0.038)
Screening failure1 20 0–40 Beta (40, 160)
Prevalence of glaucoma2 See Table 3 ± 50 Normal (prevalence, 0.1 · prevalence)
Prevalence of suspected glaucoma3 4 2–6 Beta (40, 960)
Overall prevalence of severe visual disability4
among glaucoma patients aged over 70 years
12 8–16 Normal (prevalence, 0.1 · prevalence)
Incidence of glaucoma5  ± 50 Normal (incidence, 0.1 · incidence)
Progressive changes* for treated eyes per 5 years6
(both eyes)
34 18–45 Normal (0.34, 0.034)
Progressive changes* for untreated eyes per 5 years6
(both eyes)
41 21–62 Normal (0.41, 0.04)
Probability of glaucoma patients undergoing laser
or surgical procedures7
6.75 3.4–10.1 Normal (0.0675, 0.068)
PSA, probabilistic sensitivity analysis.
Sources: 1Tuulonen et al. (2003); 2Quigley & Vitale (1997); 3Mitchell et al (1996); 4Hirvela¨ (1995); 5Leske et al. (1981); 6 Heijl et al. (2002),
CNTG (1998); 7Finnish Health Care Register (2003).
*The rationale for progression rates is as follows. The evidence of early, moderate and advanced stages of glaucoma in the population-based
studies is extremely limited and variable regarding how these stages are deﬁned, how long glaucoma patients stay in each state and what is the
proportion of glaucoma patients in each state. Instead of trying to make the best educated guess of these factors and increasing the complexity of
the model, we decided to assume a linear manner of progression and estimated the progression rates from the two treatment–no treatment studies
(CNTG 1998, Heijl et al. 2002). However, in these randomized controlled trials (i.e. in ideal settings) the progression rates were reported for one
eye only (i.e. not per patients’ two eyes, which determines both the HRQoL and visual disability). It is very hard to say whether the estimates of
our model reﬂect the real world because the results for CNTS were reported in eight different ways with very variable progression rates between
treated and non-treated eyes. There is a lack of adequate evidence on the values of most of the important parameters needed in the model.
See Data sources and assumptions.
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with sensitivity analyses. They
revealed that the cost utility of an
organized screening programme is
sensitive to several parameters, especi-
ally screening cost and speciﬁcity of
diagnostic tests.
Limitations of the study
An economic evaluation of glaucoma
screening typically encounters several
difﬁcult problems. Diagnostic studies
of glaucoma lack a generally appro-
ved deﬁnition of the disease (Bathija
et al. 1998). Because of different deﬁ-
nitions, studies also offer variable esti-
mates for prevalence and incidence.
Moreover, a majority of diagnostic
studies have been performed on prese-
lected patient populations, which may
lead to over-optimistic results (Siddiq-
ui et al. 2005).
The estimates of the sensitivity and
speciﬁcity of diagnostic tests vary sub-
stantially in the literature. Our esti-
mates are based on an earlier
systematic review of the literature, the
Finnish EBM Guideline for Glaucoma
(Tuulonen et al. 2003). However, no
meta-analyses were undertaken to
obtain the values for sensitivity and
speciﬁcity for the different tests. Our
results are based on the optimistic
assumption that evaluating informa-
tion from three different examinations
(nerve ﬁbre layer, optic disc and visual
ﬁeld) (Tuulonen et al. 2003; Robin
et al. 2005) would bring speciﬁcity
and sensitivity to an acceptable level.
Compared to studies performed in
academic centres, in everyday practice
ophthalmologists often apply a non-
optimal combination of diagnostic
and follow-up tests and do so far less
frequently, leading to a low speciﬁcity.
Therefore, the current opportunistic
case ﬁnding produces a large number
Table 5. Input cost data used in the model.
Variable Description Cost (€)
Range for sensitivity
analysis (€) and
parameters of gamma
distribution (a, b) in PSA Source
Cost of follow-up The mean cost of follow-up,
including all examinations
256 ⁄ year 120–400 (11.65, 22) Finnish Health Care
Registry (2003)
Cost of glaucoma
medication
Mean cost of glaucoma medication.
For laser-treated or operated
patients it was assumed that
medication cost is 50% of mean
cost for ﬁrst 5 years, 70% for next
5 years and then 100%
302 ⁄ year 200–400 (12, 25) Finnish Social
Insurance
Institution (2003)
Cost of glaucoma
operation
Weighted mean cost of laser therapy
(unit cost €146) and glaucoma
operation (unit cost €1333)
614 300–1000 (20, 30) Finnish Health
Care Register (2003)
Cost of screening See Table 6 37 15–100 (6, 6.2)
Cost of visual
disability
Direct visual disability-related
costs of diabetic patients
(assumed to be similar in
glaucoma-induced visual disability)
11 867 ⁄ year 6000–18000 (10,1186.7) Pajunpa¨a¨ (1999)
PSA, probabilistic sensitivity analysis.
Table 6. Resource requirements and costs of carrying out annually 269 300 primary screenings
and 27 000 secondary screenings in 14 screening centres throughout the country.
Resource Units Unit cost (€ ⁄ year)
Medical staff*
Nurses 31 600
Humphrey + digital camera or HRT 167
FDT + digital camera or HRT 104
Secretaries 32 28 600
Ophthalmologists 5 82 000
Equipment
Humphrey visual ﬁeld instruments 77 5198
FDT visual ﬁeld instruments 14 3100
Digital cameras 31 6930
Heidelberg Retina Tomograph III 31 8201
Digital imaging and information systems 31 11 550
Autorefractometers 14 2300
Slits lamps 14 3580
Other costs
Overall expenses 269 300 2
Rent of 14 screening centres§ 14
Humphrey + digital camera or HRT 16 926
FDT + digital camera or HRT 9085
Travelling 269 300 5.90–
Cost per screen using Humphrey + digital camera
or HRT
37
Cost per screen using FDT + digital camera or HRT 29
*(a) 210 working days per year; (b) 38.25 working hours per week for nurses and secretaries,
37 hours per week for ophthalmologists; (c) time required per person screened during the ﬁrst
screening: nurse ⁄ photographer 55 min (imaging, visual ﬁeld examination and intraocular pres-
sure measurement), secretary 10 min, ophthalmologist 1 min (analysis of test results); (d) time
required per person screened in the second screening: nurse ⁄ photographer 45 min (imaging, vis-
ual ﬁeld examination and intraocular pressure measurement), secretary 10 min, ophthalmologist
6 min (analysis of test results).
Annual gross salary including social security expenses of 35%.
Annuity with lifespan of 5 years, interest rate of 5% and scrap value of 0.
§Based on average all-inclusive (heating, electricity etc) rent ⁄m2 of premises (Statistics of Finland).
–Hujanen (2003).
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of non-glaucomatous subjects, who
are treated for glaucoma. For
instance, in Finland there are already
more individuals on glaucoma medica-
tion than there should be ‘true’ glau-
coma patients on the basis of
epidemiological studies (Table 3), and
yet only half of patients with manifest
glaucoma have been diagnosed. In our
model, the non-glaucomatous individ-
uals on medication were screened in
order to better target the treatment to
the ‘right’ subjects – patients with
manifest glaucoma. Whether this
approach would be justiﬁed in the real
world is, of course, an ethical question
that should be considered alongside
cost-effectiveness issues.
We had to assume that the technol-
ogy, effect of therapy, relative prices,
demography and life expectancy would
Table 7. The health-related quality of life (HRQoL) scores in different Markov states and age groups (for descriptions of Markov states, see
Table 1).
Age group
Markov states
1, 2 3, 5 4, 6 7 8, 9, 11, 12 10 13
50–54 0.916 0.905 0.903 0.904 0.894 0.893 0.743
55–59 0.909 0.897 0.896 0.896 0.887 0.885 0.735
60–64 0.894 0.882 0.881 0.882 0.872 0.870 0.723
65–69 0.871 0.859 0.858 0.859 0.849 0.847 0.707
70–74 0.840 0.828 0.827 0.828 0.818 0.816 0.686
75–79 0.801 0.790 0.788 0.789 0.779 0.778 0.660
80–84 0.755 0.743 0.742 0.743 0.733 0.731 0.631
85–89 0.700 0.689 0.687 0.688 0.678 0.677 0.597
Table 8. Base case results.
Strategy
Cost (€)
(1)
Incremental
cost (€)
(2)
QALYs
(3)
Incremental
QALYs
(4)
ICUR (€)
(2) ⁄ (4)
Years of
visual disability
(6)
Years of
visual disability
avoided
(7)
ICER (€)
(2) ⁄ (7)
Opportunistic case ﬁnding 853.00 10.13495 0.02715
Screening 883.32 30.32 10.13831 0.00336 9024 0.02622 0.00093 32 602
QALYs, quality-adjusted life years; ICUR, incremental cost-utility ratio; ICER, incremental cost-effectiveness ratio.
Table 9. Results of one-way sensitivity analysis.
Variable Range
ICUR* for lower
bound of range
ICUR for upper
bound of range Remarks
Discount rate 0–0.1 €3877 €13 734 3.5 %: €7582
Follow-up cost €120–€400 €16 581 €1021
Prevalence of glaucoma ± 50% €4506 €38 047 From Quigley & Vitale (1997)
Prevalence of suspected glaucoma 0.02–0.06 €34 552 Screening dominant
Screening cost €15–€100 Screening dominant €20 634 Threshold value: €19
Overall speciﬁcity of two serial
screening tests
0.925–0.999 Screening dominated Screening dominant Speciﬁcity of 1st screening test: 0.75–0.99
Speciﬁcity of 2nd screening test: 0.70–0.90
*Incremental cost-utility ratio (ICUR): DC ⁄ DE, where DC is incremental cost of screening compared to opportunistic case ﬁnding (OCF) and
DE is incremental effectiveness (in terms of quality-adjusted life years gained) of screening compared to OCF. Screening is (strongly) dominant if
screening is less costly and more effective than OCF and (strongly) dominated in the opposite case.
Table 10. Threshold analyses by age cohorts: screening dominant within the range of the variables.
Age cohort
Discount
rate
Follow-up
cost
Prevalence of
glaucoma
Prevalence of
suspected
glaucoma
Screening
cost
Overall speciﬁcity of two serial screening tests
Screening dominated Screening dominant
50–54 years No No No No No < 0.975 > 0.991
55–59 years No No No No No < 0.963 > 0.988
60–64 years < 0.01 > €371 No > 0.05 < €23 < 0.954 > 0.983
65–69 years < 0.095 > €172 < +50% Yes < €50 < 0.941 > 0.975
70–74 years Yes Yes < +50% Yes < €78 < 0.919 > 0.961
75–79 years Yes Yes < +50% Yes Yes < 0.881 > 0.943
Acta Ophthalmologica Scandinavica 2007
515
remain unchanged over the 10–40 year
time horizon of the model. This
assumption will hardly hold in reality.
The HRQoL scores associated with
different Markov states were estimated
from a representative population
health survey and were based on
self-reported diagnosis and use of
medication and other treatments.
According to the survey respondents,
their diagnosis was conﬁrmed by an
ophthalmologist, but obviously the
method of conﬁrmation is not known.
Besides, the data did not allow a dis-
tinction between the states with and
without progression. Therefore, we
used the same HRQoL score in both
progressive and non-progressive cases.
Although counterintuitive, this assu-
mption is, at least in early glaucoma,
supported by the Early Manifest
Glaucoma Trial Group report, in
which Hyman et al. (2005) found that
visual ﬁeld defect progression did not
affect vision-targeted HRQoL until
visual acuity was affected or with
increase of the mean deviation of the
better eye. This pattern is also clear in
the HRQoL scores we derived.
Although Kobelt et al. (2006) found
a decrease in the HRQoL scores
with increasing glaucomatous damage
(stages 1–4), the difference was
statistically signiﬁcant only in the
most severe glaucoma (stage 5).
Besides, sensitivity analyses conﬁrmed
that the base case results are quite
robust to variation in the quality of
life scores within their conﬁdence
intervals.
Moreover, our data produced a
slightly higher HRQoL score for the
state ‘undiagnosed glaucoma with
progression’ than for the state ‘drug-
treated glaucoma with progression’. It
is difﬁcult to judge whether this is a
real difference (e.g. because of side-
effects or nuisance caused by therapy
and frequent follow-up visits, or
consciousness of suffering from a
progressive disease) or an artefact of
our data. However, this difference was
very small and the results of probabi-
listic sensitivity analysis conﬁrmed the
insigniﬁcance of the difference. In
cases of diagnosed early glaucoma,
vision-targeted HRQoL have been
reported to be similar for treated and
untreated patients (Hyman et al.
2005).
Comparison to previous literature
For several reasons, it is difﬁcult to
compare our results with earlier ﬁndings.
Gottlieb et al. (1983) concluded that
the cost per year of vision saved was
lowest in the group aged 55–70 and
screening targeted only at the over 70
age groups was probably not cost
effective. In contrast, screening in our
model becomes more cost effective
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Fig. 2. Cost-effectiveness plane in the base case analysis (5 year age groups between 50 and
79 years are invited to screening at 5 year intervals, input parameters in Tables 3–6). In 24% of
simulated cases, screening was both less costly and more effective (quadrant IV); in 7% of
simulated cases, screening was less costly and less effective (quadrant III); in 47% of simulated
cases, screening was more costly and more effective (quadrant II); in 22% of simulated cases,
screening was more costly and less effective (quadrant I).
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Fig. 3. Cost-effectiveness plane comparing age groups 50–54 (invited to screening six times)
and 75–79 years (invited to screening once; input parameters in Tables 3–6). In age group 75–
79 years screening was both less costly and more effective in 80% of simulated cases (quadrant
IV); in 19% of simulated cases, screening was less costly and less effective (quadrant III); in
1% of simulated cases, screening was more costly and more effective (quadrant II); in 0.2% of
simulated cases, screening was more costly and less effective (quadrant I). In age group 50–54
years the rates were 5%, 2%, 57% and 37%, respectively.
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with increasing age. This discrepancy
can be explained by a host of differ-
ences in data and methodology, such
as measure of effectiveness, screening
frequency [Gottlieb et al. (1983)
screened only once in each age group]
and estimates of prevalence (ours are
about double). Moreover, Gottlieb
et al. (1983) did not consider the cost
of blindness that would be saved if
blindness is prevented.
In a Canadian study, modelling was
used to project the effectiveness and
costs of 12 screening scenarios (Boivin
et al. 1996). The conclusion was that
cost effectiveness of most screening
programmes considered would not be
competitive, but screening is presuma-
bly more cost effective when it is lim-
ited to older age groups (65–79 years)
and carried out less frequently. This
conclusion is basically in line with
ours, although the authors used a nar-
row measure of effectiveness (years of
blindness avoided) and more frequent
screening.
Tuck & Crick (1997) estimated the
cost per true positive case using differ-
ent combinations of three main tests
(ophthalmoscopy, tonometry and peri-
metry). However, they did not consi-
der the costs and effectiveness of
follow-up and treatment and thus
addressed a different issue to that con-
sidered here.
Meaning of the study
The study shows that the cost utility
of glaucoma screening depends essen-
tially on the screening cost and specif-
icity of diagnostic tests, but also on
several other parameters. Great atten-
tion should be paid to getting realistic
estimates for these parameters. Policy
makers can use the results and model
to choose which (if any) age groups
are appropriate for screening given
their willingness to pay for a QALY
or avoided visual disability.
Unanswered questions and future research
The generalizability of the results
should be evaluated in other settings
while considering local features, such
as systems of opportunistic case ﬁnd-
ing. A randomized screening trial run
in several European countries would
be the best study design and give the
most reliable evidence of the cost
effectiveness of screening in preventing
glaucoma-induced visual disability.
Simultaneously, the sensitivity and
speciﬁcity of diagnostic tests and their
combinations could be evaluated in
large non-selected populations. Estab-
lishing a gold-standard deﬁnition of
glaucoma would be essential.
The HRQoL scores associated with
different Markov states should be
measured directly with a generic
instrument applicable to cost-utility
analysis among an adequate number
of individuals assigned by ophthal-
mologists to these states. That would
certainly add credibility to the results.
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